Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Central Nervous System Neoplasms 3 Brain Neoplasms 3 Glioma 2 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Skin Neoplasms 1 Sarcoma 1 Pinealoma 1 Neuroma, Acoustic 1 Neoplasms, Germ Cell and Embryonal 1 Mouth Neoplasms 1 Meningioma 1 Melanoma 1 Medulloblastoma 1 Glioblastoma 1 Ependymoma 1 Craniopharyngioma 1 Carcinoma, Squamous Cell 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Astrocytoma 1

Interventions

Doxorubicin 142 Ifosfamide 85 Radiotherapy 82 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 40 Etoposide 39 Docetaxel 39 Vincristine 37 Trabectedin 37 Cisplatin 35 Nivolumab 32 Magnetic Resonance Spectroscopy 26 Irinotecan 26 Carboplatin 25 Temozolomide 23 Surgical Procedures, Operative 23 Radiation 22 Ipilimumab 22 Bevacizumab 20 Blood Specimen Collection 19 Granulocyte Colony-Stimulating Factor 18 Biopsy 18 eribulin 17 Sirolimus 17 Mesna 17 Melphalan 17 Dactinomycin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × tozuleristide × Clear all

NCT02464332 2016-05-26

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Withdrawn

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡